TG Therapeutics, Inc.
NASDAQ:TGTX
32.38 (USD) • At close September 8, 2025
Overzicht | Financiële gegevens
| Bedrijfsnaam | TG Therapeutics, Inc. |
| Symbool | TGTX |
| Munteenheid | USD |
| Prijs | 32.38 |
| Beurswaarde | 5,137,605,080 |
| Dividendpercentage | 0% |
| 52-weken bereik | 21.16 - 46.48 |
| Industrie | Biotechnology |
| Sector | Healthcare |
| CEO | Mr. Michael S. Weiss Esq. |
| Website | https://www.tgtherapeutics.com |
An error occurred while fetching data.
Over TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)







